A Phase 1, Open-Label, Fixed-Sequence, Crossover Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inducer of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Trial Profile

A Phase 1, Open-Label, Fixed-Sequence, Crossover Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inducer of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Mifepristone (Primary) ; Rifampicin
  • Indications Breast cancer; Cushing syndrome; Induced abortion; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 02 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 28 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top